Camelliti, Simone
Le Noci, Valentino
Bianchi, Francesca
Moscheni, Claudia
Arnaboldi, Francesca
Gagliano, Nicoletta
Balsari, Andrea
Garassino, Marina Chiara
Tagliabue, Elda
Sfondrini, Lucia
Sommariva, Michele http://orcid.org/0000-0002-7622-0996
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (20554)
Text and Data Mining valid from 2020-11-09
Version of Record valid from 2020-11-09
Article History
Received: 18 June 2020
Accepted: 25 September 2020
First Online: 9 November 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Marina Chiara Garassino declares personal financial interests with the following organizations: AstraZeneca, MSD International GmbH, BMS, Boehringer Ingelheim Italia S.p. A, Celgene, Eli Lilly, Ignyta, Incyte, Inivata, MedImmune, Novartis, Pfizer, Roche, and Takeda; she also declares institutional financial interests with the following organizations: Eli Lilly, MSD, Pfizer (MISP), AstraZeneca, MSD International GmbH, BMS, Boehringer Ingelheim Italia S.p. A, Celgene, Ignyta, Incyte, Inivata, MedImmune, Novartis, Pfizer, Roche, Takeda, Tiziana, and Foundation Medicine.All the other authors declare that they have no potential competing interests.